Biomea Fusion Inc logo

BMEA - Biomea Fusion Inc Share Price

$16.38 -0.3  -1.5%

Last Trade - 11/05/21

Small Cap
Market Cap £338.8m
Enterprise Value £338.8m
Revenue £n/a
Position in Universe 3574th / 6852
Unlock BMEA Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BiomeaFusion Inc revenues was not reported. Net loss increasedfrom $1.2M to $5.3M. Higher net loss reflects Research anddevelopment increase from $1.1M to $3.7M (expense), Generaland administrative increase from $103K to $1.7M (expense).Basic Earnings per Share excluding Extraordinary Itemsdecreased from -$0.04 to -$0.19.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BMEA Revenue Unlock BMEA Revenue

Net Income

BMEA Net Income Unlock BMEA Revenue

Normalised EPS

BMEA Normalised EPS Unlock BMEA Revenue

PE Ratio Range

BMEA PE Ratio Range Unlock BMEA Revenue

Dividend Yield Range

BMEA Dividend Yield Range Unlock BMEA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BMEA EPS Forecasts Unlock BMEA Revenue
Profile Summary

Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing two other preclinical irreversible programs for the treatment of select cancers.

Last Annual December 31st, 2020
Last Interim January 1st, 1970
Incorporated August 9, 2017
Public Since April 16, 2021
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 28,767,867
Free Float (0.0%)
Eligible for
BMEA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BMEA
Upcoming Events for BMEA
Frequently Asked Questions for Biomea Fusion Inc
What is the Biomea Fusion Inc share price?

As of 11/05/21, shares in Biomea Fusion Inc are trading at $16.38, giving the company a market capitalisation of £338.8m. This share price information is delayed by 15 minutes.

How has the Biomea Fusion Inc share price performed this year?

Shares in Biomea Fusion Inc are currently trading at $16.38 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomea Fusion Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Biomea Fusion Inc?

There are no analysts currently covering Biomea Fusion Inc.

When will Biomea Fusion Inc next release its financial results?

It is not known when Biomea Fusion Inc will next release financial results.

What is the Biomea Fusion Inc dividend yield?

Biomea Fusion Inc does not currently pay a dividend.

Does Biomea Fusion Inc pay a dividend?

Biomea Fusion Inc does not currently pay a dividend.

When does Biomea Fusion Inc next pay dividends?

Biomea Fusion Inc does not currently pay a dividend.

How do I buy Biomea Fusion Inc shares?

To buy shares in Biomea Fusion Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biomea Fusion Inc?

Shares in Biomea Fusion Inc are currently trading at $16.38, giving the company a market capitalisation of £338.8m.

Where are Biomea Fusion Inc shares listed? Where are Biomea Fusion Inc shares listed?

Here are the trading details for Biomea Fusion Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BMEA
What kind of share is Biomea Fusion Inc?

Based on an overall assessment of its quality, value and momentum, Biomea Fusion Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biomea Fusion Inc share price forecast 2021?

We were not able to load any forecast data for Biomea Fusion Inc.

How can I tell whether the Biomea Fusion Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomea Fusion Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $16.38, shares in Biomea Fusion Inc are trading at -2.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biomea Fusion Inc PE Ratio?

We were not able to find PE ratio data for Biomea Fusion Inc.

Who are the key directors of Biomea Fusion Inc?

Biomea Fusion Inc's management team is headed by:

Thomas Butler - CEO
Ramses Erdtmann - PRE
Heow Tan - CTO
Sunny Ryan - SVF
Naomi Cretcher - VOP
Who are the major shareholders of Biomea Fusion Inc?

Here are the top five shareholders of Biomea Fusion Inc based on the size of their shareholding:

A2A Pharmaceuticals Inc Corporation
Percentage owned: 15.17% (4.37m shares)
Biomea Health, L.L.C. Corporation
Percentage owned: 15.17% (4.37m shares)
Cormorant Asset Management, LP Hedge Fund
Percentage owned: 7.89% (2.27m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 7.26% (2.09m shares)
Butler (Thomas) Individual Investor
Percentage owned: 1.36% (392k shares)
Similar to BMEA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.